Literature DB >> 18844615

HBV A1762T, G1764A mutations are a valuable biomarker for identifying a subset of male HBsAg carriers at extremely high risk of hepatocellular carcinoma: a prospective study.

Zhong-Liao Fang1, Caroline A Sabin, Bai-Qing Dong, Lian-Ying Ge, Shao-Chao Wei, Qin-Yan Chen, Kong-Xiong Fang, Jin-Ye Yang, Xue-Yan Wang, Tim J Harrison.   

Abstract

OBJECTIVES: Surveillance of hepatocellular carcinoma (HCC) can detect small tumors for resection but at a huge cost of health resources. The challenge is to reduce the surveillance population. We reported that 96% of HCC patients but only 24% of controls were infected with the hepatitis B virus (HBV) with A(1762)T, G(1764)A mutations in Guangxi, China. It is likely to be extremely beneficial in terms of cost and resources if a significant number of tumors can be detected early by screening this selected population. Our aim is to test this hypothesis.
METHODS: A cohort of 2,258 hepatitis B surface antigen-positive subjects aged 30-55 yr was recruited in Guangxi. Following evaluation of virological parameters at baseline, HCC is diagnosed by 6-monthly measurements of serum alpha-fetoprotein levels and ultrasonographic examinations.
RESULTS: Sixty-one cases of HCC were diagnosed after 36 months of follow-up. The HCC rate was higher in the mutant than wild-type group (P < 0.001, rate ratio [RR] 6.23, 95% confidence interval [CI] 2.83-13.68). The HCC rate in the male mutant group was higher than that in the male wild-type group (P < 0.001, RR 11.54, 95% CI 3.58-37.24). Specifically, 93.3% of male cases are infected with the mutant. Multivariate analyses showed that in men, increasing age and A(1762)T, G(1764)A double mutations are independently associated with developing HCC.
CONCLUSIONS: HBV A(1762)T, G(1764)A mutations constitute a valuable biomarker to identify a subset of male HBsAg carriers aged >30 yr at extremely high risk of HCC in Guangxi, and likely elsewhere.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18844615      PMCID: PMC2566798          DOI: 10.1111/j.1572-0241.2008.01974.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  33 in total

1.  Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience.

Authors:  M F Yuen; C C Cheng; I J Lauder; S K Lam; C G Ooi; C L Lai
Journal:  Hepatology       Date:  2000-02       Impact factor: 17.425

Review 2.  The epidemiology and prevention of hepatocellular carcinoma.

Authors:  A Monto; T L Wright
Journal:  Semin Oncol       Date:  2001-10       Impact factor: 4.929

3.  Clinical and virological characteristics of hepatitis B virus subgenotypes Ba, C1, and C2 in China.

Authors:  Zhanhui Wang; Yasuhito Tanaka; Yuehua Huang; Fuat Kurbanov; Jinjun Chen; Guobing Zeng; Bin Zhou; Masashi Mizokami; Jinlin Hou
Journal:  J Clin Microbiol       Date:  2007-03-21       Impact factor: 5.948

4.  Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America.

Authors:  Patricia Arauz-Ruiz; Helene Norder; Betty H Robertson; Lars O Magnius
Journal:  J Gen Virol       Date:  2002-08       Impact factor: 3.891

Review 5.  Hepatitis B viral genotypes: clinical relevance and molecular characteristics.

Authors:  Jia-Horng Kao
Journal:  J Gastroenterol Hepatol       Date:  2002-06       Impact factor: 4.029

6.  Hepatitis B virus (HBV) genotypes/subgenotypes in China: mutations in core promoter and precore/core and their clinical implications.

Authors:  Jing Yuan; Boping Zhou; Yasuhito Tanaka; Fuat Kurbanov; Etsuro Orito; Zuojiong Gong; Liumei Xu; Jian Lu; Xiaoling Jiang; Weizhen Lai; Masashi Mizokami
Journal:  J Clin Virol       Date:  2007-04-23       Impact factor: 3.168

7.  [Relationship between hot spot mutation in hepatitis B virus basic core promotor and HBeAg status].

Authors:  G Z Gong; Q Ding; X H Zheng; L Y Li; L Y Lai; L Huang
Journal:  Hunan Yi Ke Da Xue Xue Bao       Date:  2000-12-28

8.  Core promoter mutations (A(1762)T and G(1764)A) and viral genotype in chronic hepatitis B and hepatocellular carcinoma in Guangxi, China.

Authors:  Zhong-Liao Fang; Jinye Yang; Xianmin Ge; Hui Zhuang; Jian Gong; Rongcheng Li; Roger Ling; Tim J Harrison
Journal:  J Med Virol       Date:  2002-09       Impact factor: 2.327

9.  Temporal relationship between hepatitis B virus enhancer II/basal core promoter sequence variation and risk of hepatocellular carcinoma.

Authors:  Y-C Chou; M-W Yu; C-F Wu; S-Y Yang; C-L Lin; C-J Liu; W-L Shih; P-J Chen; Y-F Liaw; C-J Chen
Journal:  Gut       Date:  2007-05-14       Impact factor: 23.059

10.  Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease.

Authors:  Hajime Sumi; Osamu Yokosuka; Naohiko Seki; Makoto Arai; Fumio Imazeki; Tomoko Kurihara; Tatsuo Kanda; Kenichi Fukai; Masaki Kato; Hiromitsu Saisho
Journal:  Hepatology       Date:  2003-01       Impact factor: 17.425

View more
  54 in total

1.  Impact of hepatitis B virus (HBV) x gene mutations on hepatocellular carcinoma development in chronic HBV infection.

Authors:  Jong-Han Lee; Kwang-Hyub Han; Jae Myun Lee; Jeon Han Park; Hyon-Suk Kim
Journal:  Clin Vaccine Immunol       Date:  2011-04-13

Review 2.  Overview of hepatitis B virus mutations and their implications in the management of infection.

Authors:  Patrizia Caligiuri; Rita Cerruti; Giancarlo Icardi; Bianca Bruzzone
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

3.  Association of hepatitis B virus pre-S deletions with the development of hepatocellular carcinoma in Qidong, China.

Authors:  Li-Shuai Qu; Jin-Xia Liu; Tao-Tao Liu; Xi-Zhong Shen; Tao-Yang Chen; Zheng-Pin Ni; Cui-Hua Lu
Journal:  PLoS One       Date:  2014-05-21       Impact factor: 3.240

4.  Ultrasensitive quantification of hepatitis B virus A1762T/G1764A mutant by a SimpleProbe PCR using a wild-type-selective PCR blocker and a primer-blocker-probe partial-overlap approach.

Authors:  Hui Nie; Alison A Evans; W Thomas London; Timothy M Block; Xiangdong David Ren
Journal:  J Clin Microbiol       Date:  2011-05-11       Impact factor: 5.948

5.  Clinical relevance and public health significance of hepatitis B virus genomic variations.

Authors:  Guang-Wen Cao
Journal:  World J Gastroenterol       Date:  2009-12-14       Impact factor: 5.742

Review 6.  DNA markers in molecular diagnostics for hepatocellular carcinoma.

Authors:  Ying-Hsiu Su; Selena Y Lin; Wei Song; Surbhi Jain
Journal:  Expert Rev Mol Diagn       Date:  2014-08-07       Impact factor: 5.225

7.  Prevalent HBV point mutations and mutation combinations at BCP/preC region and their association with liver disease progression.

Authors:  Dake Zhang; Sufang Ma; Xin Zhang; Hanqing Zhao; Huiguo Ding; Changqing Zeng
Journal:  BMC Infect Dis       Date:  2010-09-16       Impact factor: 3.090

8.  Association of miRNA-122-binding site polymorphism at the interleukin-1 α gene and its interaction with hepatitis B virus mutations with hepatocellular carcinoma risk.

Authors:  Yan Du; Xue Han; Rui Pu; Jiaxin Xie; Yuwei Zhang; Guangwen Cao
Journal:  Front Med       Date:  2014-04-21       Impact factor: 4.592

9.  Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis.

Authors:  Shijian Liu; Hongwei Zhang; Chunying Gu; Jianhua Yin; Yongchao He; Jiaxin Xie; Guangwen Cao
Journal:  J Natl Cancer Inst       Date:  2009-07-02       Impact factor: 13.506

10.  Hepatitis B virus pre-S deletion mutations are a risk factor for hepatocellular carcinoma: a matched nested case-control study.

Authors:  Zhong-Liao Fang; Caroline A Sabin; Bai-Qing Dong; Shao-Chao Wei; Qin-Yan Chen; Kong-Xiong Fang; Jin-Ye Yang; Jian Huang; Xue-Yan Wang; Tim J Harrison
Journal:  J Gen Virol       Date:  2008-11       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.